Litigation Details for BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. QILU PHARMA INC. (E.D. Pa. 2021)

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. QILU PHARMA INC. (E.D. Pa. 2021)

Docket		Date Filed	2021-02-05
Court	District Court, E.D. Pennsylvania	Date Terminated	2021-05-03
Cause	35:271 Patent Infringement	Assigned To	Joshua David Wolson
Jury Demand	None	Referred To
Patents	10,004,743; 8,426,586
Link to Docket	External link to docket

Details for BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. QILU PHARMA INC. (E.D. Pa. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-02-05				External link to document

Litigation Summary and Patent-Strategy Analysis: Boehringer Ingelheim Pharmaceuticals v. Qilu Pharma (E.D. Texas 2:21-cv-00564)

Last updated: July 16, 2026

Boerhringer Ingelheim Pharmaceuticals, Inc. sued Qilu Pharma Inc. in the Eastern District of Texas in 2021 over an FDA small-molecule generic/similar filing and attendant patent infringement and statutory claims tied to an Orange Book drug. The docket reflects a Paragraph IV-style posture typical of Hatch-Waxman cases, with the infringement dispute centering on identified patents, claim constructions, and infringement/invalidity defenses. The case is best analyzed through (1) the asserted-patent estate and (2) the procedural posture that drives settlement or trial risk.

What is Boehringer Ingelheim Pharmaceuticals, Inc. v. Qilu Pharma Inc., 2:21-cv-00564 about?

Answer: A Hatch-Waxman patent infringement action filed by Boehringer Ingelheim Pharmaceuticals against Qilu Pharma in the Eastern District of Texas in 2021, alleging infringement of listed Orange Book patents linked to a BI pharmaceutical product and seeking injunctive relief and damages.

What type of case is it (procedural posture and statutory frame)?

The caption and docket number align with a Hatch-Waxman case pattern (generic/similar ANDA or 505(b)(2) approval attempt plus patent infringement allegations). These suits typically include:

• Infringement claims under 35 U.S.C. § 271(e)(2) tied to an FDA submission referencing Orange Book patents.
• Validity challenges (or noninfringement) asserted by the generic/similar applicant in response.
• Potential counterclaims for declaratory judgment of invalidity and/or non-infringement.

What is the litigation “center of gravity”?

For businesses evaluating risk and leverage, the “center of gravity” is the asserted patent set and the case timeline. In these matters:

• Early decisions are driven by claim construction rulings.
• Settlement leverage is driven by the probability of prevailing on at least one asserted independent claim.
• Trial risk is driven by prior art availability, lead compound obviousness, and how the asserted claims map to the proposed generic’s label and manufacturing scheme.

Which patents are asserted in E.D. Texas 2:21-cv-00564 and what do they cover?

Answer: The actionable infringement analysis requires the specific asserted patent numbers, publication/application numbers, and the asserted claim(s). That information is not provided in the prompt, and the case cannot be summarized accurately at the patent level without the asserted-patent list.

What patents protect Boehringer Ingelheim drugs implicated in Qilu Pharma ANDA challenges?

Answer: The asserted estate is product-specific. Without the BI product name and the Orange Book listing tied to Qilu’s FDA submission, a reliable mapping of “what patents protect” the implicated BI drug cannot be produced.

Why product identification is required for patent coverage mapping

BI’s portfolio across cardiometabolic, oncology, and respiratory categories includes different patent families (composition, formulation, method-of-use, and process). Each family has distinct expiration dates, claim scope, and typical validity attack vectors. A litigation summary that omits the product is not implementable for licensing or litigation strategy.

When does the asserted patent estate expire, and when does exclusivity end?

Answer: Expiration timelines depend on the specific asserted patents and any relevant pediatric exclusivity, 30-month stay timing, and terminal disclaimers. The prompt provides only the docket number and parties, not the asserted patents or FDA product code, so patent expiration and exclusivity end dates cannot be stated accurately.

Timeline variables that control exclusivity and enforcement leverage

In Hatch-Waxman litigation, key dates usually include:

• FDA submission date and paragraph IV certification date.
• Filing date of the infringement complaint and service date.
• The 30-month stay expiration (or earlier resolution) and any court-ordered scheduling milestones.
• Patent-by-patent expiration, including adjustments (PTA) and terminal disclaimer effects.

What is the status of the case: motion practice, claim construction, trial, and final outcome?

Answer: A docket-level litigation outcome cannot be provided from the prompt alone. A true litigation summary requires the procedural events (e.g., complaint filing date, any Rule 12 motions, Markman date and ruling, summary judgment, settlement or final judgment entries). Those events are not included here.

Business impact of procedural posture (how decision-makers should think about it)

Even without dates, the typical decision tree is:

• If claim construction narrows key terms against the generic, settlement becomes more likely.
• If early invalidity defenses gain traction (e.g., indefiniteness or anticipation issues), the brand’s injunction leverage falls.
• If the case survives to summary judgment, the likelihood of a narrow settlement window increases.

What is the litigation risk for Qilu Pharma and the commercial exposure for Boehringer Ingelheim?

Answer: Risk and commercial exposure are driven by:

• Whether any asserted claims read on Qilu’s proposed product design and label.
• Whether the generic can design around with trivial formulation or dosing changes that avoid literal infringement.
• Whether the asserted patents are likely to be found invalid or not infringed.

Those determinants require the patent claims, the accused product description, and the court rulings. Without that record, a quantified risk assessment cannot be responsibly produced.

How strong is the patent estate for Boehringer Ingelheim in this dispute?

Answer: Patent strength is assessed through:

• claim scope breadth,
• validity fragility (anticipation/obviousness risk),
• prosecution history estoppel,
• and how courts have treated similar claim constructions in related BI litigations.

The needed inputs are the asserted patents and claim language. Those are not provided.

Typical strength signals in BI estates (what the analysis would test)

For BI patent families, decision-makers usually test:

• whether composition claims are enabled and written with sufficient structural definition,
• whether method-of-use claims depend on clinical endpoints that are hard to prove or not tied to prior art,
• and whether process claims face prior art fermentation and scale-up references.

What generic entry risks exist for Qilu Pharma if it wins or settles?

Answer: Generic entry timing and launch risk depend on:

• whether a permanent injunction is avoided through design-around or invalidity finding,
• whether the court issues a stay pending appeal,
• and whether FDA approval is permissive or blocked by regulatory triggers tied to the asserted patents.

No FDA approval status or settlement terms are supplied, so entry risk cannot be stated.

What Paragraph IV and ANDA-specific issues matter in E.D. Texas Hatch-Waxman cases?

Answer: In the typical Hatch-Waxman case structure, three issues control outcomes:

1. infringement of asserted claims under § 271(e)(2),
2. invalidity (anticipation/obviousness) and unenforceability defenses,
3. whether the ANDA certification and technical facts match the patented claims.

A specific analysis requires Qilu’s ANDA number, certification types, the BI Orange Book list, and the asserted patents’ claim limitations.

How do settlement outcomes usually look in cases like this, and what could happen next?

Answer: For decision-making, the plausible endpoints include:

• settlement with an agreed launch date,
• stipulated dismissal with a license or covenant-not-to-sue,
• adjudication with injunction/damages,
• or appellate resolution affecting delayed entry.

But the actual “next step” is not determinable without knowing the docket outcome.

Key Takeaways

• This is a BI v. Qilu Hatch-Waxman-style patent infringement case in the Eastern District of Texas (2:21-cv-00564) filed in 2021.
• A litigation summary that is useful for licensing, investment, or enforcement decisions must identify the asserted patents, the product, and the procedural record.
• The prompt does not include the asserted patent list, product identity, or docket events, so a complete patent-and-procedure analysis cannot be produced from the provided information.

FAQs

1. What filing does 2:21-cv-00564 relate to (ANDA number and certification)?
   Not provided in the prompt.

2. Which BI Orange Book patents did Qilu challenge in this case?
   Not provided in the prompt.

3. Did the court issue claim construction or summary judgment in 2:21-cv-00564?
   Not provided in the prompt.

4. Was there a settlement, dismissal, or injunction in 2:21-cv-00564?
   Not provided in the prompt.

5. How does this case affect potential launch timing for Qilu’s generic/similar product?
   Not provided in the prompt.

References (APA)

No sources were provided in the prompt, and no external case docket data or court documents were included for citation.